The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Acquired mutations associated with resistance to BTKi in patients with CLL
Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses acquired mutations that underlie resistance to BTK inhibitors (BTKi) in patients with chronic lymphocytic leukemia (CLL). Mutations arising at position C481 of BTK can cause resistance to covalent BTKi like ibrutinib, acalabrutinib, and zanubrutinib. Resistance to the non-covalent BTKi pirtobrutinib could lead to resistance against subsequent covalent inhibitors, emphasizing the crucial need for optimal sequencing strategies, although the non-covalent BTKi nemtabrutinib overcomes this. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Honoraria: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Travel support: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca; Research Funding: Amgen, Abbvie, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Sunesis, AstraZeneca.
